Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$120,000.00

Evaluating the real-world effectiveness of the human papillomavirus (HPV) vaccine among gay, bisexual, and other men who have sex with men in three large Canadian cities

FY 2024-25

Summary
Human papillomavirus (HPV) is the most common sexually transmitted infection globally, disproportionately affecting gay, bisexual, and other men who have sex with men (MSM). MSM are at higher risk for HPV and HPV-associated diseases, such as anal and oropharyngeal cancer, partly due to higher rates of HIV infection in this population. To protect this high-risk group, HPV vaccines have been offered in Canada for males under 26 years old since 2015-2016. While clinical trials have shown that the HPV vaccine provides over 60% protection among healthy MSM with few lifetime sex partners, there is limited research on its effectiveness in real-world settings. This gap is especially significant for older sexually active MSM who have previously been exposed to HPV and for individuals living with HIV. My PhD project aims to fill this critical gap by leveraging data from the Engage-HPV study, a community-based cohort of MSM aged 16 and older in Montreal, Toronto, and Vancouver. I will determine how well the HPV vaccine protects against new and persistent HPV infection over four years, focusing on differences across age, HIV status, and sites of infection (oral or anal). I will use data from each annual study visit, where participants self-collected oral and anal samples for HPV testing and completed questionnaires about their sexual history and HPV vaccination status. I will estimate the percentage of MSM with an HPV infection at the start of the study, and those who get a new and persistent HPV infection during the four-year follow-up period. The findings from my research will inform vaccine policy in Canada, as it may support extending current vaccination programs to include older MSM and improving strategies to reduce HPV-related diseases in this vulnerable high-risk population.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
518269
Name
Khayargoli Pranamika
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Doctoral Research Awards - B
Projecttitle
Evaluating the real-world effectiveness of the human papillomavirus (HPV) vaccine among gay, bisexual, and other men who have sex with men in three large Canadian cities
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Anal Cancer; Hiv; Human Papillomavirus (Hpv); Longitudinal Study; Men Who Have Sex With Men; Oropharyngeal Cancer; Persistent Infection; Sexually Transmitted Infections; Vaccine; Vaccine Effectiveness
Abstract
Human papillomavirus (HPV) is the most common sexually transmitted infection globally, disproportionately affecting gay, bisexual, and other men who have sex with men (MSM). MSM are at higher risk for HPV and HPV-associated diseases, such as anal and oropharyngeal cancer, partly due to higher rates of HIV infection in this population. To protect this high-risk group, HPV vaccines have been offered in Canada for males under 26 years old since 2015-2016. While clinical trials have shown that the HPV vaccine provides over 60% protection among healthy MSM with few lifetime sex partners, there is limited research on its effectiveness in real-world settings. This gap is especially significant for older sexually active MSM who have previously been exposed to HPV and for individuals living with HIV. My PhD project aims to fill this critical gap by leveraging data from the Engage-HPV study, a community-based cohort of MSM aged 16 and older in Montreal, Toronto, and Vancouver. I will determine how well the HPV vaccine protects against new and persistent HPV infection over four years, focusing on differences across age, HIV status, and sites of infection (oral or anal). I will use data from each annual study visit, where participants self-collected oral and anal samples for HPV testing and completed questionnaires about their sexual history and HPV vaccination status. I will estimate the percentage of MSM with an HPV infection at the start of the study, and those who get a new and persistent HPV infection during the four-year follow-up period. The findings from my research will inform vaccine policy in Canada, as it may support extending current vaccination programs to include older MSM and improving strategies to reduce HPV-related diseases in this vulnerable high-risk population.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Khayargoli, Pranamika
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~